Overview
FDA & Trial Timeline
3 eventsPREVYMIS: FDA approved
prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older and weighing at least 6 kg who are CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT)
Pedmark: FDA approved
To reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors
Astagraf XL: FDA approved
prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants in adult and pediatric patients.
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
4 availableCytoGam
Attenuation of primary CMV disease associated with kidney transplant recipients who are seronegative for CMV and who receive a kidney from a CMV seropositve donor
MAVYRET
MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with acute or chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with c…
MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with acute or chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A).
Harvoni
genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin
Astagraf XL
prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants in adult and pediatric patients.
Clinical Trials
View all trials with filters →No actively recruiting trials found for Recurrent hepatitis C virus induced liver disease in liver transplant recipients at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Recurrent hepatitis C virus induced liver disease in liver transplant recipients.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
3 resourcesRibavirin
Merck
Chronic Hepatitis C
Travel Grants
No travel grants are currently matched to Recurrent hepatitis C virus induced liver disease in liver transplant recipients.
Community
No community posts yet. Be the first to share your experience with Recurrent hepatitis C virus induced liver disease in liver transplant recipients.
Start the conversation →Latest news about Recurrent hepatitis C virus induced liver disease in liver transplant recipients
No recent news articles for Recurrent hepatitis C virus induced liver disease in liver transplant recipients.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Recurrent hepatitis C virus induced liver disease in liver transplant recipients
What treatment and support options exist for Recurrent hepatitis C virus induced liver disease in liver transplant recipients?
3 patient support programs are currently tracked on UniteRare for Recurrent hepatitis C virus induced liver disease in liver transplant recipients. See the treatments and support programs sections for copay assistance, eligibility, and contact details.